Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Last trade$7.43
Day change-$0.12 (-1.59%)
Day range$7.26 – $7.76
Volume6,471,055
Market cap$3.49B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.49B
Price / earnings
—
Price / book
4.3×
Price / sales
9.22×
EV / sales
9.06×
EV / EBITDA
-17.81×
Profitability
Earnings per share
-$0.48
Return on assets
-22.25%
Return on equity
-27.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.2×
Quick ratio
4.67×
Cash ratio
0.55×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$216.06M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IOVA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$121.47M
$99.31M
$71.43M
$86.77M
$67.46M
$59.95M
$49.32M
$73.69M
Cost of revenue
$48.03M
$43.6M
$42.5M
$43.11M
$38.48M
$48.88M
$42.72M
$37.79M
Gross profit
$73.44M
$55.72M
$28.93M
$43.66M
$28.98M
$11.07M
$6.61M
$35.91M
Selling, general and administrative
$38.58M
$39.27M
$38.95M
$36.4M
$34.56M
$37.57M
$43.8M
$42.32M
Research and development
$49.34M
$58.85M
$62.49M
$71.2M
$75.17M
$77.93M
$75.97M
$71.01M
Total operating expenses
$97.41M
$107.62M
$109.98M
$117.12M
$123.88M
$124.85M
$127.83M
$122.48M
Operating income
-$23.97M
-$51.91M
-$81.04M
-$73.46M
-$94.9M
-$113.77M
-$121.22M
-$86.58M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$21.66M
-$48.69M
-$79.71M
-$71.72M
-$93.66M
-$109.67M
-$118M
-$77M
Income taxes
$614K
-$1.37M
-$665K
$184K
-$2.41M
$1.99M
-$1.84M
$1.56M
Net income
-$22.27M
-$47.32M
-$79.05M
-$71.9M
-$91.25M
-$111.66M
-$116.16M
-$78.56M
Net income attributable to common shareholders
-$22.27M
-$47.32M
-$79.05M
-$71.9M
-$91.25M
-$111.66M
-$116.16M
-$78.56M
EBITDA
-$14.47M
-$42.41M
-$72.5M
-$63.53M
-$81.16M
-$104.42M
-$113.16M
-$72.58M
Basic earnings per share
-$0.05
-$0.11
-$0.19
-$0.18
-$0.25
-$0.33
-$0.36
-$0.26
Diluted earnings per share
-$0.05
-$0.11
-$0.19
-$0.18
-$0.25
-$0.33
-$0.36
-$0.26
Recent news
Company coverage with links to the original publishers.
Iovance Biotherapeutics (IOVA) reported Q3 2026 revenues of $121.5M, surpassing estimates, with Amtagvi sales growing 77% to $102M. The company reaffirmed full-year revenue guidance of $410-$420M, highlighted improving gross margins at 60%, and advanced its pipeline with lung cancer and sarcoma trials targeting regulatory submissions in 2027-2029. Management expects cash resources to support operations into 2029.
Amneal Pharmaceuticals (AMRX) reported Q3 2026 adjusted EPS of 26 cents, beating consensus estimates of 24 cents, with revenues of $862.6 million up 10% year-over-year. The company raised its 2026 guidance for net revenue, adjusted EBITDA, and adjusted EPS, citing strong growth in Affordable Medicines and Specialty segments. Recent FDA approvals and the acquisition of Kashiv BioSciences strengthen its biosimilar portfolio, with launches expected through 2029.
Viatris (VTRS) is expected to report Q3 2026 revenues of $3.78 billion and earnings of 64 cents per share, likely beating consensus estimates. The company faces headwinds from FDA import alerts affecting 11 products, supply disruptions, and competitive pressures, but these are expected to be offset by new product growth and strength in branded markets, particularly in Greater China and Emerging Markets.
Iovance Biotherapeutics is projected to report Q3 2026 revenues of $117.7 million with a loss of 9 cents per share, expected to beat earnings estimates. Amtagvi is anticipated to drive ~$95 million in sales, while Proleukin could contribute ~$22 million. The company has a positive Earnings ESP of +44.44% and Zacks Rank #2, with investors awaiting pipeline updates on combination studies for melanoma and other cancer indications.
Gilead Sciences beat Q3 earnings expectations with adjusted EPS of $2.55 and revenues of $8.3 billion, driven by strong HIV drug sales (up 18% to $6.25 billion) led by Biktarvy, Descovy, and Yeztugo. Trodelvy oncology sales jumped 42% and Livdelzi grew 93%, prompting the company to raise 2026 product sales guidance to $31-$31.3 billion. However, Cell Therapy revenues declined 18% amid competitive pressures, and the company faces a $1.5 billion revenue headwind for Biktarvy in 2028 from Medicare pricing changes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.